Skip to content
NewsBlazeAU – Lifestyle
Author:
Orum Therapeutics
Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate
October 13, 2026
Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
August 28, 2026